Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | CO3.Al.Na.2HO |
| Molecular Weight | 143.9949 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].[OH-].[Na+].[Al+3].[O-]C([O-])=O
InChI
InChIKey=SEIGJEJVIMIXIU-UHFFFAOYSA-J
InChI=1S/CH2O3.Al.Na.2H2O/c2-1(3)4;;;;/h(H2,2,3,4);;;2*1H2/q;+3;+1;;/p-4
Potash (Dihydroxyaluminum Sodium Carbonate), a component of
Kompensan-S Forte in Germany, is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Kompensan-S Forte is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL261 |
|||
Target ID: CHEMBL205 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Kompensan Approved UseGastrointestinal disorders: Dyspepsia, Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Hyperphosphatemia |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Studies of neutralizing properties of antacid preparations. Part 4: Application of Weibull distribution function to neutralization of dihydroxyaluminum sodium carbonate. | 1988 Jul |
|
| Automation of dihydroxyaluminum sodium carbonate analysis in antacid tablets by energy dispersive X-ray fluorescence. | 1990 May-Jun |
|
| Effect of pepsin on the kinetics of HCl neutralization by dihydroxyaluminum sodium carbonate, hydrotalcite and dihydroxyaluminum aminoacetate. | 1991 |
Sample Use Guides
Usual Adult Dose for Dyspepsia: 500 to 600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Duodenal Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Erosive Esophagitis: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastric Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastroesophageal Reflux Disease: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Zollinger-Ellison Syndrome: 500 to 3600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Hyperphosphatemia: 500 to 1000 mg orally 4 times a day, with meals and at bedtime. The dosage should be titrated to the serum phosphate level.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
||
|
NCI_THESAURUS |
C29701
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23163
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | RxNorm | ||
|
C76484
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | |||
|
240-536-4
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | |||
|
C016386
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | |||
|
539-68-4
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
SUPERSEDED | |||
|
100000079203
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | |||
|
84H8Z9550J
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | |||
|
m4472
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB13596MIG
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | |||
|
DTXSID101340737
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | |||
|
12011-77-7
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
ALTERNATIVE | |||
|
84H8Z9550J
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | |||
|
16482-55-6
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY | |||
|
9793815
Created by
admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
